PRODUCT INFORMATION



ACBI1

Item No. 36612

CAS Registry No.:	2375564-55-7
Formal Name:	(2S,4R)-N-(2-(2-(4-((4-(3-amino-6-(2-
	hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)
	methyl)phenoxy)ethoxy)-4-(4-methylthiazol-
	5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-
	1-carboxamido)-3,3-dimethylbutanoyl)-4-
	hydroxypyrrolidine-2-carboxamide
MF:	$C_{49}H_{58}FN_9O_7S$
FW:	936.1
Purity:	≥95%
UV/Vis.:	λ_{max} : 266 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.	

Laboratory Procedures

ACBI1 is supplied as a solid. A stock solution may be made by dissolving the ACBI1 in the solvent of choice, which should be purged with an inert gas. ACBI1 is soluble in DMSO.

Description

ACBI1 is a proteolysis-targeting chimera (PROTAC) composed of a ligand for BRM, also known as SMARCA2, BRG1, also known as SMARCA4, and polybromo-1D (PBRM1), which are components of switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes, conjugated to a von Hippel-Lindau (VHL) E3 ligase ligand.¹ It induces degradation of BRM, BRG1, and PBRM1 with 50% degradation concentration (DC50) values of 6, 11, and 32 nM, respectively, in MV4-11 acute myeloid leukemia (AML) cells. ACBI1 decreases the proliferation of MV4-11 cells (IC50 = 28 nM) but is inactive against NCI H1703 non-small cell lung cancer (NSCLC) cells, which do not express BRM or BRG1. It prevents exhaustion of isolated human CD8⁺ T cells when used at concentrations of 50 and 100 nM.²

References

- 1. Farnaby, W., Koegl, M., Roy, M.J., et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15(7), 672-680 (2019).
- 2. Battistello, E., Hixon, K.A., Comstock, D.E., et al. Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Mol. Cell. S1097-2765(23), 00153-3 (2023).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Suyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/21/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM